Skip to main content
Erschienen in:

01.02.2011

Clinical Trials Update AHA Congress 2010

verfasst von: John D. Horowitz, Robert S. Rosenson, John J. V. McMurray, Nikolaus Marx, Willem J. Remme

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The clinical trials described in this article were presented at the Late Breaking Trials and the Clinical Science: Clinical Reports sessions of the American Heart Association Congress held in November 2010 in Chicago. The sessions and topics chosen for this article reflect the scope of interest of Cardiovascular Drugs and Therapy. The presentations should be considered preliminary, as further analyses may be done, which could alter the final publication of the results of these studies. PROTECT (ProBNP Outpatient Tailored Chronic Heart Failure Therapy) was designed to test the hypothesis that adjustment of intensity of chronic heart failure (HF) therapy on the basis of NT-proBNP plasma level monitoring would improve outcomes. The results provided some support of this concept, but needs further evaluation in larger, blinded trials. REVEAL (Reduction of Infarct Expansion and Ventricular Remodeling with erythropoietin after large myocardial infarctions) evaluated in the clinical setting of ischemia-reperfusion following STEMI that erythropoietin could salvage ischemic myocardium. The results did not show a reduction in infarct size, but, in contrast, an increase in adverse event rates in the erythropoietin group. GRAVITAS (Gauging Responsiveness with a VerifyNow assay-Impact on Thrombosis and Safety trial) investigated the effect of a standard vs. high maintenance clopidogrel dose in patients with stable myocardial ischemia or NSTEMI and drug–eluting stent insertion. Patients with high PRU values as determined by VerfyNow assay were randomized to 75 mg or 150 mg clopidogrel daily. The study did not show a significant difference in primary event rate between both groups. The Cholesterol Treatment Trialists’ Collaboration Studies group evaluated the concept proposed in the JUPITER study that HDL levels on statin treatment may not provide useful prognostic information. The CTTC in a large sample size of statin-treated patients observed, on the contrary, a significantly increased risk of CV events, even in patients with low LDL cholesterol levels. DEFINE (Determining the Efficacy and Tolerability of CETP inhibition with Anacetrapib) evaluated possible safety aspects with the CETP inhibitor anacetrapib (increase in blood pressure). The study did not show adverse safety aspects, but significantly reduced LDL cholesterol and increased HDL cholesterol levels. ASSERT, a phase 2 dose–ranging study, investigated whether RVX-208 would increase Apo-A1 production. Apo-A1 may induce cholesterol efflux from macrophages and facilitate atherosclerosis regression. The study did not meet its primary endpoint, but significant prominent effects on lipids were found. ASCEND-HF was a large trial of nesiritide in >7000 patients with acute heart failure. The study did not show convincing symptom benefit, but on the other hand did not show harmful effects of nesiritide. EMPHASIS-HF evaluated the long term effects of eplerenone in patients with mild (NYHA class II) heart failure and systolic dysfunction. The study was prematurely ended because of highly significant beneficial effects. CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) is the first human study with gene transfer of SERCA2a (AVV1/SERCA2a: Mydicar). In a small placebo-controlled dose-ranging study in advanced heart failure patients a multiple endpoint analysis provided positive effects of the highest dose on symptomatic, functional and structural efficacy endpoints without adverse effects.
Literatur
1.
Zurück zum Zitat Zannad F, McMurray JJ, Krum H, et al. Epleronone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef Zannad F, McMurray JJ, Krum H, et al. Epleronone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef
2.
Zurück zum Zitat Melloni C, Rao SV, Povsic TJ, et al. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodelling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J. 2010;160:795–803.PubMedCrossRef Melloni C, Rao SV, Povsic TJ, et al. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodelling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J. 2010;160:795–803.PubMedCrossRef
3.
Zurück zum Zitat Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009;157:818–24.PubMedCrossRef Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009;157:818–24.PubMedCrossRef
4.
Zurück zum Zitat CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med. 2010;363:930–42.PubMedCrossRef CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med. 2010;363:930–42.PubMedCrossRef
5.
Zurück zum Zitat Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006;151:556–63.PubMedCrossRef Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006;151:556–63.PubMedCrossRef
6.
Zurück zum Zitat Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.PubMedCrossRef Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.PubMedCrossRef
7.
Zurück zum Zitat Keech AC, Rosenson R, Barnes E, et al. Low HDL-C carries residual risk even at target LDL-C among patients in the Cholesterol Treatment Trialists’ Collaboration Studies. Circulation. 2010;122:A19010. Keech AC, Rosenson R, Barnes E, et al. Low HDL-C carries residual risk even at target LDL-C among patients in the Cholesterol Treatment Trialists’ Collaboration Studies. Circulation. 2010;122:A19010.
8.
Zurück zum Zitat Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesterol ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907–14.PubMedCrossRef Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesterol ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907–14.PubMedCrossRef
9.
Zurück zum Zitat Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–60.PubMedCrossRef Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–60.PubMedCrossRef
10.
Zurück zum Zitat Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patient with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.PubMedCrossRef Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patient with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.PubMedCrossRef
11.
Zurück zum Zitat Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–54.PubMedCrossRef Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–54.PubMedCrossRef
12.
Zurück zum Zitat Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux in HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–8.PubMedCrossRef Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux in HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–8.PubMedCrossRef
13.
Zurück zum Zitat Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. ArteriosclerThrombVasc Biol. 2010;30:1430–8. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. ArteriosclerThrombVasc Biol. 2010;30:1430–8.
14.
Zurück zum Zitat Vucic E, Rosenson RS. Recombinant HDL formulations. Curr Athero Rep. 2011;13:81–7.CrossRef Vucic E, Rosenson RS. Recombinant HDL formulations. Curr Athero Rep. 2011;13:81–7.CrossRef
15.
Zurück zum Zitat Nissen S, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled clinical trial. JAMA. 2003;290:2292–300.PubMedCrossRef Nissen S, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled clinical trial. JAMA. 2003;290:2292–300.PubMedCrossRef
16.
Zurück zum Zitat Nichols SJ, Ballantyne CM, Kastelein JJ, et al. Results of the first major clinical trial of an oral agent inducing Apo A1 synthesis: A new approach to HDL raising and CV risk modification. Circulation. 2010;122:2220.CrossRef Nichols SJ, Ballantyne CM, Kastelein JJ, et al. Results of the first major clinical trial of an oral agent inducing Apo A1 synthesis: A new approach to HDL raising and CV risk modification. Circulation. 2010;122:2220.CrossRef
17.
Zurück zum Zitat Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler ThrombVasc Biol. 2003;23:847–52.CrossRef Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler ThrombVasc Biol. 2003;23:847–52.CrossRef
18.
Zurück zum Zitat Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–91.PubMedCrossRef Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–91.PubMedCrossRef
19.
Zurück zum Zitat Pitt B, Remme WJ, Zannad F, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef Pitt B, Remme WJ, Zannad F, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef
20.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ, for the Randomized ALdactone Evaluation Study (RALES) Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRef Pitt B, Zannad F, Remme WJ, for the Randomized ALdactone Evaluation Study (RALES) Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRef
21.
Zurück zum Zitat Kawakase Y, Ly H, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:554–65. Kawakase Y, Ly H, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:554–65.
22.
Zurück zum Zitat Cohn J. Unconventional end points in cardiovascular trials: should we be moving away from morbidity and mortality? J Card Fail. 2009;15:199–205.PubMedCrossRef Cohn J. Unconventional end points in cardiovascular trials: should we be moving away from morbidity and mortality? J Card Fail. 2009;15:199–205.PubMedCrossRef
23.
Zurück zum Zitat Jaski B, Jessup M, Mancini D, et al. for the CUPID Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15:171–81.PubMedCrossRef Jaski B, Jessup M, Mancini D, et al. for the CUPID Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15:171–81.PubMedCrossRef
Metadaten
Titel
Clinical Trials Update AHA Congress 2010
verfasst von
John D. Horowitz
Robert S. Rosenson
John J. V. McMurray
Nikolaus Marx
Willem J. Remme
Publikationsdatum
01.02.2011
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 1/2011
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6285-9

Weitere Artikel der Ausgabe 1/2011

Cardiovascular Drugs and Therapy 1/2011 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Aggressive Blutdrucksenkung bei Risikopersonen?

12.07.2024 Arterielle Hypertonie Nachrichten

Geht es nach einer aktuellen chinesischen Studie, ist die Einstellung des systolischen Blutdrucks bei Risikopersonen auf Werte unter 120 mmHg mit weniger kardiovaskulären Ereignissen assoziiert als die Senkung auf Werte unter 140 mmHg.

Mehr Komplikationen beim akuten Koronarsyndrom ohne klassische Risikofaktoren

11.07.2024 Akutes Koronarsyndrom Nachrichten

Ein steigender Anteil von Personen mit akutem Koronarsyndrom (ACS) weist keine modifizierbaren Risikofaktoren auf. Wie sich das auf die Prognose auswirkt, wurde anhand eines australischen PCI-Registers untersucht. 

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Bewusstsein während Reanimation – gibt es "typische" Fälle?

10.07.2024 Kardiopulmonale Reanimation Nachrichten

Australische Rettungsdienstdaten deuten darauf hin, dass sich Fälle, in denen eine laufende Reanimation Anzeichen von Bewusstsein induziert, von anderen Wiederbelebungsfällen unterscheiden könnten. Etwa mit Blick auf die Überlebenschancen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.